URGN

NEUTRALEarnings

UroGen Pharma Ltd.

2026-07-29

Price

$40.45

-1.05%

This is the 2026-07-29 snapshot — the signals and analysis for URGN as of this single trading day.

View full URGN research hub →

Score1.9Noise

Signals2/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.4xvs 20d avg

Analysis

UroGen Pharma (URGN) is exhibiting high-conviction price discovery, digesting recent gains ahead of its Q2 earnings report on August 5. Despite a cautious macro regime dominated by geopolitical tensions, the stock shows robust institutional absorption, evidenced by its +12.5% relative strength versus the SPY and a potent 'Perfect Stack' of technical signals. A major mid-July U.S. patent allowance extending protection for ZUSDURI into 2044 serves as the structural catalyst underpinning this sustained momentum.

Fired Signals

GOLDEN CROSSPERFECT STACKSELLER FATIGUEBARGAIN HUNTER

Key Takeaways

Bullish momentum is validated by a Perfect Stack and Golden Cross, demonstrating relative strength (+12.5% vs SPY) against a volatile macro backdrop.
A recent U.S. patent allowance securing protection for ZUSDURI and UGN-103 until 2044 fundamentally de-risks the long-term pipeline.
The upcoming Q2 earnings call on August 5 is the critical near-term catalyst that will test the stock's $37.41 support base.

← Back to 2026-07-29 View Full URGN History →Yahoo Finance &nearr;